Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently amended) A compound having the structure (I):

$$\begin{array}{c}
R^3 \\
O O O \\
Y \longrightarrow R^1
\end{array}$$
(I)

and pharmaceutically acceptable derivatives thereof;

wherein \mathbb{R}^1 is hydrogen, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety;

n is 1-5;

R² is hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety;

X is -O-, -C(R^{2A})₂-, -S-, or -NR^{2A}-, wherein R^{2A} is hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety;

or wherein two or more occurrences of R² and R^{2A}, taken together, form an alicyclic or heterocyclic moiety, or an aryl or heteroaryl moiety;

R³ is an <u>aryl or heteroaryl moiety substituted with a moiety having the structure -L-R^{4A}, wherein L is a linker, and R^{4A} comprises a metal chelator aliphatic, alieyelic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; and</u>

Y is aromatic moiety.

2. (Previously presented) The compound of claim 1, wherein:

R¹ is hydrogen, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, - (aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety;

R² is hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or - (heteroaliphatic)heteroaryl moiety;

X is -O-, -C(R^{2A})₂-, -S-, or -NR^{2A}-, wherein R^{2A} is hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, - (aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety;

or wherein two or more occurrences of R^2 and R^{2A} , taken together, form an alicyclic or heterocyclic moiety, or an aryl or heteroaryl moiety;

R³ is an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety; and Y is aryl, -(aliphatic)aryl, or -(heteroaliphatic)aryl moiety.

3. (Original) The compound of claim 1, wherein the compound has the structure as shown in formula (Ia):

$$\begin{array}{c}
R^3 \\
O \\
\downarrow O \\
\uparrow O \\
\downarrow O \\
\uparrow O \\
\downarrow O \\
\uparrow O \\
\uparrow O \\
\downarrow O \\
\uparrow O \\
\downarrow O \\
\uparrow O \\
\downarrow O \\$$

4. (Original) The compound of claim 1, wherein the compound has the structure as shown in formula (Ib):

The compound of claim 1, wherein when R³ represents a (Previously presented) 5. phenyl group substituted with a moiety having the structure -P-Q, the following groups do not occur simultaneously as defined:

P is selected from the group consisting of substituted or unsubstituted C₄-C₈ alkylene, C₄-C₈ alkenylene, C₄-C₈ alkynylene, and -R-T-U-, wherein R and U are independently absent or represent a C2-C7 alkylene, a C2-C7 alkenylene, or a C2-C7 alkynylene, and T represents O, S or NR^T, wherein R^T represents hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aralkyl, aryl or heterocyclyl; and

Q is selected from the group consisting of:

$$\begin{array}{c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

and a boronic acid moiety; wherein W is O or S; V is O, S or -NR^{Vd}, wherein R^{Vd} is hydrogen, alkyl, alkoxycarbonyl, aryloxycarbonyl, alkylsulfonyl, arylsulfonyl, or aryl; R^{Va} is hydrogen, alkyl, alkenyl, alkynyl, or aryl; R^{Vb} is hydrogen, alkyl, aryl, alkoxy, aryloxy, amino, hydroxylamino, alkoxylamino or halogen; and R^{Vc} is hydrogen, alkyl, aryl, hydroxyl, alkoxy, aryloxy or amino.

The compound of claim 1, wherein when R³ represents a phenyl group 6. (Original) substituted with a moiety having the structure -P-Q, the following groups do not occur simultaneously as defined:

P is selected from the group consisting of:

Page 4 of 33 Attorney's Docket Number: 2001180-0075 Client Reference Number: HU 1917-01/CIP and O is selected from the group consisting of:

wherein W and R^{Va-d} are as defined above; X¹ is a good leaving group (e.g., diazo, halogen, a sulfate or sulfonate ester such as a tosylate or mesylate); RVe is hydrogen, alkyl, aryl, alkoxy, aryloxy, halogen; and R^{Vf} is hydrogen, alkyl or halogen.

- The compound of claim 1, wherein Y is an aryl or heteroaryl moiety 7. (Original) substituted with Z, wherein Z is hydrogen, $-(CH_2)_qOR^Z$, $-(CH_2)_qSR^Z$, $-(CH_2)_qN(R^Z)_2$, $-C(=O)R^Z$, $-(CH_2)_qSR^Z$ C(=O)N(R^Z)₂, or an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, wherein q is 0-4, and wherein each occurrence of R² is independently hydrogen, a protecting group, a solid support unit, or an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety.
- The compound of claim 1, wherein Y is a substituted phenyl moiety and 8. (Original) the compound has the structure (II):

$$Z$$
 R^3
 R^3
 R^2
 R^1
 R^2

wherein Z is hydrogen, $-(CH_2)_qOR^Z$, $-(CH_2)_qSR^Z$, $-(CH_2)_qN(R^Z)_2$, $-C(=O)R^Z$, -C(=O)N(R^Z)₂, or an alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -

> Page 5 of 33 Attorney's Docket Number: 2001180-0075 Client Reference Number: HU 1917-01/CIP

(heteroalkyl)aryl, or –(heteroalkyl)heteroaryl moiety, wherein q is 0-4, and wherein each occurrence of R² is independently hydrogen, a protecting group, a solid support unit, or an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, - (heteroalkyl)aryl, or –(heteroalkyl)heteroaryl moiety.

9. (Original) The compound of claim 1, wherein Y is a substituted phenyl moiety and the compound has the structure (III):

wherein R^Z is hydrogen, a protecting group, a solid support unit, or an alkyl, cycloalkyl, heteroalkyl, heteroayl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or - (heteroalkyl)heteroaryl moiety.

10. (Original) The compound of claim 1, wherein Y is a substituted phenyl moiety and X is S and the compound has the structure (IV):

wherein R^Z is hydrogen, a protecting group, a solid support unit, or an alkyl, cycloalkyl, heteroalkyl, heteroayl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or - (heteroalkyl)heteroaryl moiety.

11. (Original) The compound of claim 1, wherein Y is a substituted phenyl moiety and X is $-NR^{2A}$ and the compound has the structure (V):

Page 6 of 33 Attorney's Docket Number: 2001180-0075 Client Reference Number: HU 1917-01/CIP

wherein R^Z is hydrogen, a protecting group, a solid support unit, or an alkyl, cycloalkyl, heteroalkyl, heteroacyl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or - (heteroalkyl)heteroaryl moiety.

12. (Original) The compound of claim 1, wherein Y is a substituted phenyl moiety and X is -O- and the compound has the structure (VI):

wherein R^Z is hydrogen, a protecting group, a solid support unit, or an alkyl, cycloalkyl, heteroalkyl, heteroacyl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or - (heteroalkyl)heteroaryl moiety.

13. (Original) The compound of claim 1, wherein Y is a substituted phenyl moiety and R^3 is a phenyl moiety substituted with R^4 and the compound has the structure (VII):

$$Z$$
 R^4
 $X \cdot R^2$
 (VII)

wherein R^4 is $-(CH_2)_rN(R^{4A})_2$, $-(CH_2)_rSR^{4A}$, $-(CH_2)_rOR^{4A}$, $-(CH_2)_rNR^{4A}C(=O)R^{4B}$ (CH₂)_rC(=O)N(R^{4A})₂, -S(O)₂R^{4A}, or is an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, wherein each occurrence of R^{4B} is independently hydrogen, an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety; and each occurrence of R^{4A} is independently hydrogen, a protecting group, an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or –(heteroaliphatic)heteroaryl moiety, or is –C(=O)CH(R^{4C})NH(SO₂)R^{4D}, $-SO_2R^{4C}$, $-C(=O)R^{4C}$, $-C(=O)N(R^{4C})_2$, $-C(=S)N(R^{4C})_2$, or $-C(=O)(CH_2)_tC(=O)NHR^{4C}$, wherein each occurrence of R^{4C} and R^{4D} is independently hydrogen, a protecting group, hydroxyl, protected hydroxyl, or an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, wherein r and t are each independently 0-5; and Z is hydrogen, -(CH₂)_qOR^Z, -(CH₂)_qSR^Z, $-(CH_2)_aN(R^Z)_2$, $-C(=O)R^Z$, $-C(=O)N(R^Z)_2$, or an alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, -(alkyl)aryl(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety, wherein q is 0-4, and wherein each occurrence of R² is independently hydrogen, a protecting group, a solid support unit, or an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety.

The compound of claim 13, wherein Z is -CH₂OR², and the compound has 14. (Original) the structure (VIII):


$$R^4$$

$$0 \qquad 0 \qquad X \qquad R^2$$

$$(VIII)$$

Page 8 of 33 Attorney's Docket Number: 2001180-0075 Client Reference Number: HU 1917-01/CIP wherein R^Z is hydrogen, a protecting group, a solid support unit, or an alkyl, cycloalkyl, heteroalkyl, heteroacyl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or - (heteroalkyl)heteroaryl moiety.

- 15. (Original) The compound of claim 1, wherein R¹ is hydrogen, methyl, or phenyl.
- 16. (Previously presented) The compound of claim 1, wherein X-R² has one of the structures:



The compound of claim 1, wherein R³ is one of the 17. (Previously presented) following structures:

$$\mathbb{R}^{4A}$$
 \mathbb{R}^{4A}
 \mathbb{R}^{4A}

wherein L is a substituted or unsubstituted C₄₋₈alkylene or C₄₋₈alkenylene chain wherein up to two non-adjacent methylene units are independently optionally replaced by CO, CO₂, COCO, CONR^{Z1}, OCONR^{Z1}, NR^{Z1}NR^{Z2}, NR^{Z1}NR^{Z2}CO, NR^{Z1}CO, NR^{Z1}CO₂, NR^{Z1}CONR^{Z2}, SO, SO₂, NR^{Z1}SO₂, SO₂NR^{Z1}, NR^{Z1}SO₂NR^{Z2}, O, S, or NR^{Z1}; wherein each occurrence of R^{Z1} and R²² is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl; and R^{4A} comprises a metal chelator.

- The compound of claim 17, wherein L is -18. (Previously presented) (CH₂),N(R^{4C})Alk¹-, wherein r is 0 or 1; R^{4C} is hydrogen, a nitrogen protecting group, alkyl, acyl, heteroalkyl, aryl or heteroaryl; and Alk¹ is a substituted or unsubstituted C₃₋₇alkylene or C₃₋ 7alkenylene chain wherein up to two non-adjacent methylene units are independently optionally replaced by CO, CO₂, COCO, CONR^{Z1}, OCONR^{Z1}, NR^{Z1}NR^{Z2}, NR^{Z1}NR^{Z2}CO, NR^{Z1}CO, $NR^{Z1}CO_2$, $NR^{Z1}CONR^{Z2}$, SO, SO₂, $NR^{Z1}SO_2$, SO_2NR^{Z1} , $NR^{Z1}SO_2NR^{Z2}$, O, S, or NR^{Z1} ; wherein each occurrence of R^{Z1} and R^{Z2} is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl.
- The compound of claim 17, wherein L is -19. (Previously presented) (CH₂)_rN(R^{4C})C(=0)Alk²-, wherein r is 0 or 1; R^{4C} is hydrogen, a nitrogen protecting group, alkyl, acyl, heteroalkyl, aryl or heteroaryl; and Alk² is a substituted or unsubstituted C₃₋₆alkylene or C_{3.6}alkenylene chain wherein up to two non-adjacent methylene units are independently optionally replaced by CO, CO₂, COCO, CONR²¹, OCONR²¹, NR²¹NR²², NR²¹NR²²CO, NR^{Z1}CO, NR^{Z1}CO₂, NR^{Z1}CONR^{Z2}, SO, SO₂, NR^{Z1}SO₂, SO₂NR^{Z1}, NR^{Z1}SO₂NR^{Z2}, O, S, or NR^{Z1}; wherein each occurrence of R^{Z1} and R^{Z2} is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl.

Page 11 of 33 Attorney's Docket Number: 2001180-0075 Client Reference Number: HU 1917-01/CIP

- 20. (Previously presented) The compound of claim 17, wherein L is $(CH_2)_rNHC(=O)(CH_2)_t$, wherein r is 0 or 1; and t is 3, 4, 5 or 6.
- 21. (Original) The compound of any one of claims 17-20, wherein R^{4A} is -C(=O)OR^{4B}, -C(=O)NHOR^{4B} or a moiety having the structure:

wherein each occurrence of R^{4B} is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl.

22. (Original) The compound of claim 1, wherein the compound has the structure:

$$R^4$$
 R^4
 R^5
 R^2
 R^2

wherein R^4 is $-(CH_2)_rN(R^{4A})_2$, $-(CH_2)_rSR^{4A}$, $-(CH_2)_rOR^{4A}$, $-(CH_2)_rNR^{4A}C(=O)R^{4B}$, $-(CH_2)_rC(=O)N(R^{4A})_2$, $-S(O)_2R^{4A}$, or is an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic) aryl, -(aliphatic) moiety, wherein each occurrence of R^{4B} is independently hydrogen, an aliphatic, alycyclic, heteroaliphatic) aryl, or -(aliphatic) heteroaryl, -(aliphatic) and each occurrence of R^{4A} is independently hydrogen, a protecting group, an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic) heteroar

Page 12 of 33 Attorney's Docket Number: 2001180-0075 Client Reference Number: HU 1917-01/CIP (aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, wherein r and t are each independently 0-5; and R^Z is hydrogen, a protecting group, a solid support unit, or an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety.

- The compound of claim 22, wherein R¹ is hydrogen, phenyl or methyl, R² 23. (Original) is hydrogen or a solid support unit; R² is a substituted or unsubstituted alkyl or heteroalkyl moiety, or a substituted or unsubstituted aryl or heteroaryl moiety; and R⁴ is -(CH₂)_rN(R^{4A})₂, - $(CH_2)_rSR^{4A}$, $-(CH_2)_rOR^{4A}$, $-(CH_2)_rNR^{4A}C(=O)R^{4B}$, $-(CH_2)_rC(=O)N(R^{4A})_2$, $-S(O)_2R^{4A}$, or is an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, wherein each occurrence of R^{4B} is independently hydrogen, an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety; and each occurrence of R^{4A} is independently hydrogen, a protecting group, an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, or is $-C(=O)CH(R^{4C})NH(SO_2)R^{4D}$, $-SO_2R^{4C}$, $-C(=O)R^{4C}$, $-C(=O)N(R^{4C})_2$, $-C(=O)N(R^{4$ $C(=S)N(R^{4C})_2$, or $-C(=O)(CH_2)_1C(=O)NHR^{4C}$, wherein each occurrence of R^{4C} and R^{4D} is independently hydrogen, a protecting group, hydroxyl, protected hydroxyl, or an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, wherein r and t are each independently 0-5.
- 24. (Previously presented) The compound of claim 22, wherein R⁴ represents a moiety having the structure –L-R^{4A} and the compound has the structure:

wherein L is a linker and R^{4A} comprises a metal chelator.

- 25. (Previously presented) The compound of claim 24, wherein L is a substituted or unsubstituted C₄₋₈alkylene or C₄₋₈alkenylene chain wherein up to two non-adjacent methylene units are independently optionally replaced by CO, CO₂, COCO, CONR^{Z1}, OCONR^{Z1}, NR^{Z1}NR^{Z2}, NR^{Z1}NR^{Z2}CO, NR^{Z1}CO, NR^{Z1}CO, NR^{Z1}CO₂, NR^{Z1}CONR^{Z2}, SO, SO₂, NR^{Z1}SO₂, SO₂NR^{Z1}, NR^{Z1}SO₂NR^{Z2}, O, S, or NR^{Z1}; wherein each occurrence of R^{Z1} and R^{Z2} is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl.
- 26. (Previously presented) The compound of claim 25, wherein L is $(CH_2)_tNHC(=O)(CH_2)_t$, wherein r is 0 or 1; and t is 3, 4, 5 or 6.
- 27. (Original) The compound of claim 24, wherein R^{4A} is $-C(=O)OR^{4B}$, $-C(=O)NHOR^{4B}$ or a moiety having the structure:

wherein each occurrence of R^{4B} is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl.

28. (Previously presented) The compound of claim 24, wherein the compound has the structure:

wherein r is 0 or 1; Alk¹ is a substituted or unsubstituted C₄₋₇alkylene or C₄₋₇alkenylene chain wherein up to two non-adjacent methylene units are independently optionally replaced by

CO, CO₂, COCO, CONR^{Z1}, OCONR^{Z1}, NR^{Z1}NR^{Z2}, NR^{Z1}NR^{Z2}CO, NR^{Z1}CO, NR^{Z1}CO₂, NR^{Z1}CONR^{Z2}, SO, SO₂, NR^{Z1}SO₂, SO₂NR^{Z1}, NR^{Z1}SO₂NR^{Z2}, O, S, or NR^{Z1}; wherein each occurrence of R^{Z1} and R^{Z2} is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl; R^{AA} comprises a metal chelator; and R^Z is hydrogen, a protecting group, a solid support unit, or an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, - (heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety.

29. (Previously presented) The compound of claim 28, wherein Alk^1 is a moiety having the structure $-C(=0)-Alk^2$ - and the compound has the structure:

wherein Alk² is a substituted or unsubstituted C₃₋₆alkylene or C₃₋₆alkenylene chain wherein up to two non-adjacent methylene units are independently optionally replaced by CO, CO₂, COCO, CONR^{Z1}, OCONR^{Z1}, NR^{Z1}NR^{Z2}, NR^{Z1}NR^{Z2}CO, NR^{Z1}CO, NR^{Z1}CO₂, NR^{Z1}CO₂, NR^{Z1}CONR^{Z2}, SO, SO₂, NR^{Z1}SO₂, SO₂NR^{Z1}, NR^{Z1}SO₂NR^{Z2}, O, S, or NR^{Z1}; wherein each occurrence of R^{Z1} and R^{Z2} is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl.

- 30. (Previously presented) The compound of claim 29, wherein Alk^2 is a substituted or unsubstituted C_{3-6} alkylene chain.
- 31. (Original) The compound of claim 29, wherein R^{4A} is -C(=O)OR^{4B}, -C(=O)NHOR^{4B} or a moiety having the structure:

Page 15 of 33 Attorney's Docket Number: 2001180-0075 Client Reference Number: HU 1917-01/CIP wherein each occurrence of R^{4B} is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl.

32. (Original) The compound of claim 28 having the structure:

$$\begin{array}{c} & & \\$$

wherein s is an integer from 2-5; w is an integer from 0-4; R^{4A} comprises a metal chelator and each occurrence of R^{4D} is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclic, alkenyl, alkynyl, aryl, heteroaryl, halogen, CN, NO₂, or WR^{W1} wherein W is O, S, NR^{W2}, -C(=O), -S(=O), -SO₂, -C(=O)O-, -OC(=O), -C(=O)NR^{W2}, -NR^{W2}C(=O); wherein each occurrence of R^{W1} and R^{W2} is independently hydrogen, a protecting group, a prodrug moiety or an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl or heteroaryl moiety, or, when W is NR^{W2}, R^{W1} and R^{W2}, taken together with the nitrogen atom to which they are attached, form a heterocyclic or heteroaryl moiety; or any two adjacent occurrences of R^{2B}, taken together with the atoms to which they are attached, form a substituted or unsubstituted, saturated or unsaturated alicyclic or heterocyclic moiety, or a substituted or unsubstituted aryl or heteroaryl moiety.

33. (Original) The compound of claim 32, wherein R^{4A} is -C(=O)OR^{4B}, -C(=O)NHOR^{4B} or a moiety having the structure:

wherein each occurrence of R^{4B} is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl.

Page 16 of 33 Attorney's Docket Number: 2001180-0075 Client Reference Number: HU 1917-01/CIP 34. (Original) The compound of claim 1, wherein the compound has the structure:

$$R^4$$
 R^{2A}
 R^{1}
 R^{2}
 R^{2}

wherein R^4 is $-(CH_2)_rN(R^{4A})_2$, $-(CH_2)_rSR^{4A}$, $-(CH_2)_rOR^{4A}$, $-(CH_2)_rNR^{4A}C(=O)R^{4B}$ (CH₂)_rC(=O)N(R^{4A})₂, -S(O)₂R^{4A}, or is an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, wherein each occurrence of R^{4B} is independently hydrogen, an aliphatic, alveyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety; and each occurrence of R^{4A} is independently hydrogen, a protecting group, an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or –(heteroaliphatic)heteroaryl moiety, or is –C(=O)CH(R^{4C})NH(SO₂)R^{4D}, $-SO_2R^{4C}$, $-C(=O)R^{4C}$, $-C(=O)N(R^{4C})_2$, $-C(=S)N(R^{4C})_2$, or $-C(=O)(CH_2)_1C(=O)NHR^{4C}$, wherein each occurrence of R^{4C} and R^{4D} is independently hydrogen, a protecting group, hydroxyl, protected hydroxyl, or an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, wherein r and t are each independently 0-5; R^{2A} is hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl or heteroaryl moiety; and R^Z is hydrogen, a protecting group, a solid support unit, or an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety.

35. (Original) The compound of claim 34, wherein R^1 is hydrogen, phenyl or methyl, R^2 is hydrogen or a solid support unit; R^2 is a substituted or unsubstituted alkyl or heteroalkyl moiety, or a substituted or unsubstituted aryl or heteroaryl moiety; either or both of R^2 and R^{2A} , or R^2 and R^{2A} taken together with the nitrogen atom to which they are attached, forms a substituted or unsubstituted cycloalkyl or heterocyclic moiety, or a substituted or unsubstituted aryl or heteroaryl moiety; and R^4 is $-(CH_2)_rN(R^{4A})_2$, $-(CH_2)_rSR^{4A}$, $-(CH_2)_rOR^{4A}$, -

Page 17 of 33 Attorney's Docket Number: 2001180-0075 Client Reference Number: HU 1917-01/CIP (CH₂)_tNR^{4A}C(=O)R^{4B}, -(CH₂)_tC(=O)N(R^{4A})₂, -S(O)₂R^{4A}, or is an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroaliphatic)aryl, or –(heteroaliphatic)heteroaryl moiety, wherein each occurrence of R^{4B} is independently hydrogen, an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or –(heteroaliphatic)heteroaryl moiety; and each occurrence of R^{4A} is independently hydrogen, a protecting group, an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or –(heteroaliphatic)heteroaryl moiety, or is –C(=O)CH(R^{4C})NH(SO₂)R^{4D}, -SO₂R^{4C}, -C(=O)R^{4C}, -C(=O)N(R^{4C})₂, -C(=S)N(R^{4C})₂, or –C(=O)(CH₂)_tC(=O)NHR^{4C}, wherein each occurrence of R^{4C} and R^{4D} is independently hydrogen, a protecting group, hydroxyl, protected hydroxyl, or an aliphatic, alycyclic, heteroaliphatic, heterocyclic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or –(heteroaliphatic)heteroaryl moiety, wherein r and t are each independently 0-5.

36. (Previously presented) The compound of claim 34, wherein R⁴ represents a moiety having the structure -L-R^{4A} and the compound has the structure:

wherein L is a linker and R^{4A} comprises a metal chelator.

37. (Previously presented) The compound of claim 36, wherein L is a substituted or unsubstituted C₄₋₈alkylene or C₄₋₈alkenylene chain wherein up to two non-adjacent methylene units are independently optionally replaced by CO, CO₂, COCO, CONR²¹, OCONR²¹, NR²¹NR²², NR²¹NR²²CO, NR²¹CO, NR²¹CO, NR²¹CO₂, NR²¹CONR²², SO, SO₂, NR²¹SO₂, SO₂NR²¹, NR²¹SO₂NR²², O, S, or NR²¹; wherein each occurrence of R²¹ and R²² is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl.

- 38. (Previously presented) The compound of claim 37, wherein L is $(CH_2)_tNHC(=O)(CH_2)_t$, wherein r is 0 or 1; and t is 3, 4, 5 or 6.
- 39. (Original) The compound of claim 36, wherein R^{4A} is -C(=O)OR^{4B}, -C(=O)NHOR^{4B} or a moiety having the structure:

wherein each occurrence of R^{4B} is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl.

40. (Previously presented) The compound of claim 34, wherein the compound has the structure:

wherein r is 0 or 1; Alk¹ is a substituted or unsubstituted C₄₋₇alkylene or C₄₋₇alkenylene chain wherein up to two non-adjacent methylene units are independently optionally replaced by CO, CO₂, COCO, CONR^{Z1}, OCONR^{Z1}, NR^{Z1}NR^{Z2}, NR^{Z1}NR^{Z2}CO, NR^{Z1}CO, NR^{Z1}CO₂, NR^{Z1}CO₂, NR^{Z1}CONR^{Z2}, SO, SO₂, NR^{Z1}SO₂, SO₂NR^{Z1}, NR^{Z1}SO₂NR^{Z2}, O, S, or NR^{Z1}; wherein each occurrence of R^{Z1} and R^{Z2} is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl; R^{4A} comprises a metal chelator; and R^Z is hydrogen, a protecting group, a solid support unit, or an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, - (heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety.

41. (Previously presented) The compound of claim 40, wherein Alk^1 is a moiety having the structure $-C(=O)-Alk^2$ - and the compound has the structure:

Page 19 of 33 Attorney's Docket Number: 2001180-0075 Client Reference Number: HU 1917-01/CIP

wherein Alk² is a substituted or unsubstituted C₃₋₆alkylene or C₃₋₆alkenylene chain wherein up to two non-adjacent methylene units are independently optionally replaced by CO, CO₂, COCO, CONR^{Z1}, OCONR^{Z1}, NR^{Z1}NR^{Z2}, NR^{Z1}NR^{Z2}CO, NR^{Z1}CO, NR^{Z1}CO₂, NR^{Z1}CO₂, NR^{Z1}CONR^{Z2}, SO, SO₂, NR^{Z1}SO₂, SO₂NR^{Z1}, NR^{Z1}SO₂NR^{Z2}, O, S, or NR^{Z1}; wherein each occurrence of R^{Z1} and R^{Z2} is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl.

- 42. (Previously presented) The compound of claim 41, wherein Alk^2 is a substituted or unsubstituted C_{3-6} alkylene chain.
- 43. (Original) The compound of claim 41, wherein R^{4A} is $-C(=O)OR^{4B}$, $-C(=O)NHOR^{4B}$ or a moiety having the structure:

wherein each occurrence of R^{4B} is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl.

44. (Original) The compound of claim 34 having the structure:

$$\begin{array}{c} & & & \\$$


wherein s is an integer from 2-5; w is an integer from 0-4; R^{4A} comprises a metal chelator and each occurrence of R^{4D} is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclic, alkenyl, alkynyl, aryl, heteroaryl, halogen, CN, NO₂, or WR^{W1} wherein W is O, S, NR^{W2}, -C(=O), -S(=O), -SO₂, -C(=O)O-, -OC(=O), -C(=O)NR^{W2}, -NR^{W2}C(=O); wherein each occurrence of R^{W1} and R^{W2} is independently hydrogen, a protecting group, a prodrug moiety or an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl or heteroaryl moiety, or, when W is NR^{W2}, R^{W1} and R^{W2}, taken together with the nitrogen atom to which they are attached, form a heterocyclic or heteroaryl moiety; or any two adjacent occurrences of R^{2B}, taken together with the atoms to which they are attached, form a substituted or unsubstituted, saturated or unsaturated alicyclic or heterocyclic moiety, or a substituted or unsubstituted aryl or heteroaryl moiety.

45. (Original) The compound of claim 44, wherein R^{4A} is -C(=O)OR^{4B}, -C(=O)NHOR^{4B} or a moiety having the structure:

wherein each occurrence of R^{4B} is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl.

46. (Previously presented) The compound of claim 1, 22, 32, 34 or 44, wherein R² is one of the following structures:

Page 21 of 33 Attorney's Docket Number: 2001180-0075 Client Reference Number: HU 1917-01/CIP



wherein m and p are each independently integers from 0 to 3; q_1 is an integer from 1 to 6; R^{2C} is hydrogen, lower alkyl, aryl or a nitrogen protecting group; R^{2D} is hydrogen or lower alkyl; and each occurrence of R^{2B} is independently hydrogen, halogen, -CN, -COOH, NO₂, alkyl, heteroalkyl, aryl, heteroaryl, or WR^{W1} wherein W is O, S, NR^{W2} , -C(=O), -S(=O), -SO₂, -C(=O)O-, -OC(=O), -C(=O)NR^{W2}, -NR^{W2}C(=O); wherein each occurrence of R^{W1} and R^{W2} is independently hydrogen, a protecting group, a prodrug moiety or an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl or heteroaryl moiety, or, when W is NR^{W2} , R^{W1} and R^{W2} , taken together with the nitrogen atom to which they are attached, form a heterocyclic or heteroaryl moiety; or any two adjacent occurrences of R^{2B} , taken together with the atoms to which they are attached, form a substituted or unsubstituted, saturated or unsaturated alicyclic or heterocyclic moiety, or a substituted or unsubstituted aryl or heteroaryl moiety.

47. (Original) The compound of claim 34 or 44, wherein either or both of R², R^{2A}, or R²

and R^{2A}, taken together with the nitrogen atom to which they are attached comprise exhaustive together with the nitrogen atom to which they are attached comprise exhaustive dor unsubstituted or unsubstituted aryl or heteroaryl moiety.

Page 23 of 33 Attorney's Docket Number: 2001180-0075 Client Reference Number: HU 1917-01/CIP

- 48. (Original) The compound of claim 34 or 44, wherein one or both of R² and R^{2A} is an aryl or heteroaryl moiety substituted with -COOH, halogen, alkyl, heteroalkyl, aryl, heteroaryl, OH, SH, NO₂, NH₂, or -NHC(=O)alkyl.
- 49. (Previously presented) The compound of claim 32 or 44, wherein R^{4A} is C(=O)OH, -C(=O)NHOH or a moiety having the structure:

- 50. (Previously presented) The compound of claim 32 or 44, wherein R^{4A} is C(=0)NHOH.
- 51. (Original) The compound of claim 1 having the structure:

$$\begin{array}{c|c} & & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\$$

52. (Original) The compound of claim 1 having the structure:

53. (Original) A pharmaceutical composition comprising:

a compound of any one of claims 1, 22, 32, 34 or 44; and

a pharmaceutically acceptable carrier or diluent, optionally further comprising an additional therapeutic agent.

- 54. (Original) The pharmaceutical composition of claim 53, wherein the compound is present in an amount effective to inhibit histone deacetylase activity.
- 55. (Withdrawn) A method for inhibiting histone deacetylase activity in a patient or a biological sample, comprising administering to said patient, or contacting said biological sample with an effective inhibitory amount of a compound of claim 1, 22, 32, 34 or 44.
- 56. (Withdrawn) A method for inhibiting histone deacetylase activity in a cell comprising contacting a cell with a compound of any one of claims 1, 22, 32, 34 or 44.
- 57. (Withdrawn) The method of claim 55, wherein the histone deacetylase is HDAC1 or HDAC6.
- 58. (Withdrawn) A method for treating cancer comprising: administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1, 22, 32, 34 or 44.
- 59. (Withdrawn) The method of claim 58, further comprising administering an additional therapeutic agent.
- 60. (Withdrawn and currently amended) A method for the synthesis of a compound of claim 9 wherein n is 1, and the compound has the structure:

said method comprising steps of:

providing an epoxy alcohol having the structure:

reacting the epoxy alcohol with a reagent having the structure R²XH under suitable conditions to generate a diol having the core structure:

reacting the diol with a reagent having the structure R3CH(OMe)2 under suitable conditions to generate a scaffold having the core structure:

$$\begin{array}{cccc}
R^3 \\
O & O \\
& & X \\
R^2 \\
& & (III^A)
\end{array}$$

wherein R¹ is hydrogen, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety;

R² is hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety;

X is -0-, $-C(R^{2A})_{2}$ -, -S-, or $-NR^{2A}$ -, wherein R^{2A} is hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety;

or wherein two or more occurrences of R² and R^{2A}, taken together, form an alicyclic or heterocyclic moiety, or an aryl or heteroaryl moiety;

R³ is an aryl or heteroaryl moiety substituted with a moiety having the structure -L-R^{4A}, wherein L is a linker, and R^{4A} comprises a metal chelator aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety; and

> Page 26 of 33 Attorney's Docket Number: 2001180-0075 Client Reference Number: HU 1917-01/CIP

R² is an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety and is attached to a solid support.

61. (Withdrawn) The method of claim 60, wherein R³ has the following structure:

and the method generates a scaffold having the core structure:

$$R^4$$
 $X \cdot R^2$
 QR^2

(VIII^A)

62. (Withdrawn) A method for the synthesis of a compound of claim 28 having the structure:

$$\begin{array}{c} R^{4C} \\ R^{4A} \\ R^{4C} \\ R^{4A} \\ R^{4A} \\ R^{4C} \\ R^{4A} \\ R^{4A$$

said method comprising steps of:

providing an epoxy alcohol having the structure:

reacting the epoxy alcohol with a reagent having the structure R²XH under suitable conditions to generate a diol having the core structure:

subjecting the diol with a reagent having the structure:

to suitable conditions to generate an amine having the structure:

$$X \cdot R^2$$
ORZ; and

reacting the amine with a reagent having the structure:

under suitable conditions to generate a scaffold having the core structure:

$$\begin{array}{c} & & \\$$

wherein \mathbb{R}^1 is hydrogen, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety;

R² is hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety;

X is -O-, $-C(R^{2A})_2$ -, -S-, or $-NR^{2A}$ -, wherein R^{2A} is hydrogen, a protecting group, or an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety;

or wherein two or more occurrences of R² and R^{2A}, taken together, form an alicyclic or heterocyclic moiety, or an aryl or heteroaryl moiety;

r is 0 or 1;

s is an integer from 2-5;

w is an integer from 0-4;

R^{4A} comprises a metal chelator;

each occurrence of R^{4D} is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclic, alkenyl, alkynyl, aryl, heteroaryl, halogen, CN, NO₂, or WR^{W1} wherein W is O, S, NR^{W2}, -C(=O), -S(=O), -SO₂, -C(=O)O-, -OC(=O), -C(=O)NR^{W2}, -NR^{W2}C(=O); wherein each occurrence of R^{W1} and R^{W2} is independently hydrogen, a protecting group, a prodrug moiety or an alkyl, cycloalkyl, heteroalkyl, heterocyclic, aryl or heteroaryl moiety, or, when W is NR^{W2}, R^{W1} and R^{W2}, taken together with the nitrogen atom to which they are attached, form a heterocyclic or heteroaryl moiety; or any two adjacent occurrences of R^{2B}, taken together with the atoms to which they are attached, form a substituted or unsubstituted, saturated or unsaturated alicyclic or heterocyclic moiety, or a substituted or unsubstituted aryl or heteroaryl moiety; and

R² is an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aromatic or heteroaromatic moiety and is attached to a solid support.

- 63. (Withdrawn) The method of claim 60 or 62, wherein the method further comprises cleaving the core structure from the solid support to which it is attached.
- 64. (Withdrawn) The method of claim 60 or 62, wherein R^{4A} comprises -C(=O)OR^{4B}, -C(=O)NHOR^{4B} or a moiety having the structure:

wherein each occurrence of R^{4B} is independently hydrogen, alkyl, heteroalkyl, aryl, heteroaryl or acyl.

65. (Withdrawn) The method of claim 64, wherein R^{4B} is hydrogen.